
For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.
[audio:https://www.audiomedica.com/podcasting/aha2005/Stuart_Connolly.mp3]